POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes-Reference-Cited by-同舟云学术

POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes

Published:2018-10 Issue:4 Volume:154 Page:746-748
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Cazzola Mario,Matera Maria Gabriella

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference19 articles.

1. Long-acting bronchodilators in COPD: where are we now and where are we going?;Cazzola;Breathe,2014

2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD: 2018 report. https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Published 2018. Accessed July 10, 2018.

3. Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists;Cazzola;Pulm Pharmacol Ther,2013

4. Bronchodilators, receptors and cross-talk: together is better?;Panettieri;Postgrad Med,2015

5. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi;Cazzola;Eur J Pharmacol,2014

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinically important deterioration: a composite tool for managing patients with COPD;Respiratory Medicine;2022-12

2. Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview;Expert Review of Clinical Pharmacology;2022-11-02

3. Dual bronchodilation for the treatment of COPD: From bench to bedside;British Journal of Clinical Pharmacology;2022-05-25

4. Navafenterol. Dual M3 receptor antagonist/beta2-adrenoceptor agonist (MABA), Treatment of chronic obstructive pulmonary disease;Drugs of the Future;2022

5. The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review;Journal of Thoracic Disease;2021-11